Biocon Launches Eylea Biosimilar Yesafili

An interchangeable biosimilar to Eylea is launched in the US; patient enrollment is completed in two global phase 3 clinical trials evaluating Duravyu for diabetic macular edema; and Topcon receives CE mark for a fully automated ultra-widefield retinal slit scanner.

Learn more about your ad choices. Visit megaphone.fm/adchoices